Synvista Therapeutics, Inc. (SYNI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Synvista Therapeutics, Inc. (SYNI) trades at $0.000001 with AI Score 46/100 (Grade C). Synvista Therapeutics, Inc. is a biopharmaceutical company focused on developing diagnostic tests and drugs for diabetic patients at high risk for cardiovascular disease. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SYNI: SYNI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SYNI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SYNI: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Synvista Therapeutics, Inc. (SYNI) Healthcare & Pipeline Overview
Synvista Therapeutics, Inc. is a biopharmaceutical company specializing in treatments for diabetic patients at risk of cardiovascular disease. Their pipeline features ALT-2074, a glutathione peroxidase mimetic, and Alagebrium chloride, an Advanced Glycation End-product Crosslink Breaker, both currently in Phase II clinical trials, positioning them in the competitive pharmaceuticals market.
What Is the Investment Thesis for SYNI?
Synvista Therapeutics, Inc. presents a high-risk, high-reward investment profile due to its focus on developing treatments for diabetic patients at risk of cardiovascular disease. The company's pipeline, featuring ALT-2074 and Alagebrium chloride in Phase II trials, represents potential value drivers if clinical trials are successful. However, the company's small market capitalization and OTC listing introduce significant liquidity and regulatory risks. Successful completion of Phase II trials and subsequent partnerships or acquisitions could drive significant returns. The company's beta of -5.15 suggests an inverse correlation with the market, which may offer diversification benefits in certain market conditions.
Based on FMP financials and quantitative analysis
SYNI Key Highlights
Synvista Therapeutics focuses on developing diagnostic tests and drugs for diabetic patients at high risk for cardiovascular disease.
- The company's lead product candidates, ALT-2074 and Alagebrium chloride, are both in Phase II clinical trials.
- ALT-2074 is a glutathione peroxidase mimetic for the treatment of diabetic patients with Hp2-2.
- Alagebrium chloride is an Advanced Glycation End-product Crosslink Breaker for the treatment of diastolic heart failure and diabetic nephropathy.
- Synvista Therapeutics trades on the OTC market, indicating higher risk and lower liquidity compared to major exchanges.
Who Are SYNI's Competitors?
SYNI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $46.48 | +1.68% | $206B | 51 |
| LLY Eli Lilly and Company | $1245.69 | -2.71% | $1.17T | 97 |
| SNY Sanofi | $45.44 | -0.85% | $109B | 58 |
| HEWA HealthWarehouse.com, Inc. | $0.11 | +0.00% | $6.29M | 55 |
| YI 111, Inc. | $3.44 | -1.99% | $30.1M | 44 |
| MYCOF Noveris Health Sciences Inc. | $0.73 | +0.00% | $42.7M | 48 |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $115M | 50 |
| HITI High Tide Inc. | $2.42 | -1.42% | $213M | 47 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SYNI's Key Strengths?
Focus on a specific niche within diabetes care (cardiovascular complications).
- Proprietary drug candidates in Phase II clinical trials.
- Potential for high returns if clinical trials are successful.
What Are SYNI's Weaknesses?
Small market capitalization and limited financial resources.
- Reliance on a small number of drug candidates.
- OTC listing indicates higher risk and lower liquidity.
What Could Drive SYNI Stock Higher?
Release of Phase II clinical trial results for ALT-2074.
- Announcement of potential partnerships with larger pharmaceutical companies.
- Progress on the development of a diagnostic test for cardiovascular risk in diabetic patients.
What Are the Key Risks for SYNI?
Failure of clinical trials for ALT-2074 or Alagebrium chloride.
- Competition from larger pharmaceutical companies with more resources.
- Regulatory hurdles and delays in FDA approval.
- Limited financial resources and reliance on external funding.
- Risks associated with trading on the OTC market, including low liquidity and price volatility.
What Are the Growth Opportunities for SYNI?
- Successful completion of Phase II clinical trials for ALT-2074: Positive results from the Phase II trials could lead to increased investor confidence and potential partnerships with larger pharmaceutical companies. The market for treatments targeting diabetic patients with the Hp2-2 genotype is significant, offering a substantial revenue opportunity if the drug proves effective. The timeline for Phase III trials and potential FDA approval could extend several years, but successful Phase II data would be a major catalyst.
- Advancement of Alagebrium chloride through clinical trials: Alagebrium chloride targets diastolic heart failure and diabetic nephropathy, both significant complications of diabetes. Positive clinical trial results could open up a large market opportunity. The development timeline is lengthy, but successful trials would significantly increase the company's value. The market for heart failure and diabetic nephropathy treatments is substantial and growing.
- Development and commercialization of a diagnostic test for cardiovascular risk in diabetic patients: A successful diagnostic test could provide a recurring revenue stream and differentiate Synvista from competitors. The market for diagnostic tests in diabetes is expanding, driven by the need for early detection and prevention of complications. The timeline for development and commercialization depends on regulatory approval and market adoption.
- Strategic partnerships with larger pharmaceutical companies: Collaborations with established pharmaceutical companies could provide Synvista with funding, expertise, and access to larger markets. Partnerships could accelerate the development and commercialization of Synvista's products. The pharmaceutical industry is characterized by collaborations between smaller biotech firms and larger companies, offering potential opportunities for Synvista.
- Expansion into new therapeutic areas within diabetes: Synvista could leverage its expertise in diabetes to develop treatments for other complications, such as retinopathy and neuropathy. Expanding the product pipeline would diversify the company's revenue streams and reduce its reliance on a single product. The market for diabetes treatments is broad and offers numerous opportunities for innovation.
What Are SYNI's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Specialized focus on cardiovascular complications of diabetes.
- Clinical trial data demonstrating safety and efficacy.
What Does SYNI Do?
Synvista Therapeutics, Inc., formerly known as Alteon, Inc., was founded in 1986 and is headquartered in Parsippany, New Jersey. The company operates as a product-based biopharmaceutical entity, focusing on the development of diagnostic tests and drugs aimed at identifying and treating diabetic patients who are at high risk of developing cardiovascular disease. Synvista's product pipeline includes ALT-2074, a glutathione peroxidase mimetic currently in Phase II clinical trials for treating diabetic patients with the Hp2-2 genotype. Additionally, they are developing Alagebrium chloride, also in Phase II clinical trials, targeting diastolic heart failure and diabetic nephropathy. The company is also working on a diagnostic test designed to identify and treat diabetic patients at risk of cardiovascular disease. Synvista's strategic focus on diabetes-related cardiovascular complications positions it within a niche segment of the pharmaceutical industry, addressing a significant unmet medical need.
What Products and Services Does SYNI Offer?
- Develop diagnostic tests for diabetic patients at high risk for cardiovascular disease.
- Develop drugs to treat diabetic patients at high risk for cardiovascular disease.
- Focus on glutathione peroxidase mimetics for treating diabetic patients with Hp2-2.
- Develop Advanced Glycation End-product Crosslink Breakers for treating diastolic heart failure and diabetic nephropathy.
- Conduct Phase II clinical trials for ALT-2074.
- Conduct Phase II clinical trials for Alagebrium chloride.
How Does SYNI Make Money?
- Develops and patents novel therapeutic compounds.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
What Industry Does SYNI Operate In?
Synvista Therapeutics operates within the medical pharmaceutical industry, a sector characterized by intense research and development, stringent regulatory oversight, and high capital requirements. The market for diabetes-related treatments is substantial, driven by the increasing prevalence of diabetes globally. Competition includes major pharmaceutical companies and smaller biotech firms focusing on innovative therapies. Synvista's focus on cardiovascular complications of diabetes positions it within a specialized niche, potentially offering a competitive advantage if its clinical trials are successful. The industry is also influenced by trends in personalized medicine and diagnostic testing, aligning with Synvista's development of a diagnostic test for cardiovascular risk in diabetic patients.
Who Are SYNI's Key Customers?
- Diabetic patients at high risk for cardiovascular disease.
- Hospitals and clinics specializing in diabetes care.
- Pharmaceutical companies seeking to expand their diabetes product portfolios.
Key Financial Metrics
Return on equity for Synvista Therapeutics, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. SYNI trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
SYNI Valuation & Market Position
Relative to its peer group, SYNI's quantitative score of 46/100 is below the peer average of 61/100.
Company Profile
Synvista Therapeutics, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Parsippany, US. SYNI has traded publicly since 2000.
SYNI Financials
Bull Case vs Bear Case
Bull Case
- Focus on a specific niche within diabetes care (cardiovascular complications).
- Proprietary drug candidates in Phase II clinical trials.
- Potential for high returns if clinical trials are successful.
- Upcoming: Release of Phase II clinical trial results for ALT-2074.
Bear Case
- Small market capitalization and limited financial resources.
- Reliance on a small number of drug candidates.
- OTC listing indicates higher risk and lower liquidity.
- Potential: Failure of clinical trials for ALT-2074 or Alagebrium chloride.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SYNI Latest News
No recent news available for SYNI.
SYNI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SYNI.
Price Targets
Wall Street price target analysis for SYNI.
SYNI MoonshotScore
What does this score mean?
The MoonshotScore rates SYNI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
SYNI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Synvista Therapeutics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a significantly higher risk compared to companies listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher risk of price manipulation.
- Potential for delisting or suspension of trading.
- Lack of regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if available).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Research the company's industry and market trends.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation since 1986.
- Focus on developing treatments for a specific medical need (diabetes-related cardiovascular complications).
- Drug candidates are in Phase II clinical trials.
What Investors Ask About Synvista Therapeutics, Inc. (SYNI) — Healthcare
What does the AI Score mean for SYNI?
SYNI holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Synvista Therapeutics, Inc. is a biopharmaceutical company focused on developing diagnostic tests and drugs for diabetic patients at high risk for cardiovascular disease. Their pipeline includes …
What does Synvista Therapeutics, Inc. do?
Synvista Therapeutics, Inc. is a biopharmaceutical company focused on developing diagnostic tests and drugs for diabetic patients who are at high risk of developing cardiovascular disease. Their primary focus is on developing treatments for diabetic patients with the Hp2-2 genotype and for diastolic heart failure and diabetic nephropathy.
What do analysts say about SYNI stock?
As of 2026-03-16, there is no available analyst coverage for Synvista Therapeutics, Inc. due to its OTC listing and small market capitalization. The company's valuation is highly dependent on the success of its clinical trials and its ability to secure partnerships or funding.
What are the main risks for SYNI?
The main risks for Synvista Therapeutics, Inc. include the inherent risks associated with pharmaceutical development, such as the failure of clinical trials, regulatory hurdles, and competition from larger companies with more resources. The company's reliance on a small number of drug candidates increases its vulnerability to setbacks in clinical development.
What are the key factors to evaluate for SYNI?
Synvista Therapeutics, Inc. (SYNI) holds an AI score of 46/100 (low). presents a high-risk, high-reward investment profile due to its focus on developing treatments for diabetic patients at risk of cardiovascular disease. Not financial advice.
How frequently does SYNI data refresh on this page?
SYNI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SYNI's recent stock price performance?
Synvista Therapeutics, Inc. (SYNI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a specific niche within diabetes care (cardiovascular complications). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SYNI overvalued or undervalued right now?
Synvista Therapeutics, Inc. (SYNI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SYNI before investing?
Before investing in Synvista Therapeutics, Inc. (SYNI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be incomplete or outdated.
- OTC market data may be limited and less reliable than data from major exchanges.
- AI analysis pending for SYNI.